CDK9 Inhibitor SLS009 Displays Activity in Relapsed/Refractory AML

Enrollment of patients in a phase 2 study evaluating SLS009 in relapsed/refractory AML has been completed and the agent demonstrated initial efficacy.

Related Keywords

, Angelos Stergiou ,